Exploring the Advantages of Implementing ICH Q12 by McDonagh, Susan
Level 3 
Volume 15 Issue 2 Article 9 
2020 
Exploring the Advantages of Implementing ICH Q12 
Susan McDonagh 
Technological University Dublin, anne.greene@tudublin.ie 
Follow this and additional works at: https://arrow.tudublin.ie/level3 
Recommended Citation 
McDonagh, Susan (2020) "Exploring the Advantages of Implementing ICH Q12," Level 3: Vol. 15: Iss. 2, 
Article 9. 
doi:https://doi.org/10.21427/raht-ra60 
Available at: https://arrow.tudublin.ie/level3/vol15/iss2/9 
This PART 2: Research articles from MSc cohorts on the 
Pharmaceutical Validation Technology (PVT) and 
Pharmaceutical Quality Assurance (PQA)programmes, 
PRST, TU Dublin is brought to you for free and open 
access by the Journals Published Through Arrow at 
ARROW@TU Dublin. It has been accepted for inclusion in 
Level 3 by an authorized administrator of ARROW@TU 
Dublin. For more information, please contact 
yvonne.desmond@tudublin.ie, arrow.admin@tudublin.ie, 
brian.widdis@tudublin.ie. 
This work is licensed under a Creative Commons 













Global	 regulatory	guidance	 for	post	 approval	 changes	 to	 chemisty	manufacturing	 controls	
(CMC)	 of	 commercial	 drug	products	 lack	 harmonisation.	 Implementation	of	 post-approval	
changes	are	slow	and	complex	which	can	 lead	to	supply	 issues	of	medicinal	products	with	
little	 or	 no	 continuous	 improvements	 to	 manufacturing	 processes	 being	 made.	 ICH	 Q12	
Technical	and	Regulatory	Considerations	for	Pharmaceutical	Product	Lifecycle	Management	
was	 published	 in	 November	 2019.	 This	 guideline	 provides	 a	 framework	 to	 facilitate	 the	
management	 of	 post-approval	 CMC	 changes	 in	 a	more	 predictable	 and	 efficient	manner.	
Tools	and	enablers	 in	 the	guidline	aim	to	enhance	the	transparency	between	the	 industry	
and	 the	 regulatory	 authorities	 while	 promoting	 innovation	 and	 continual	 improvementt.	
This	research	paper	explores	the	advantages	of	implementing	ICH	Q12	through	a	literature	
review,	 2	 industry	 based	 case	 studies	 that	 demonstrate	 the	 use	 of	 the	 regulatory	 tools	







of	 high	 quality	 in	 a	 cost	 effective	 manner	 to	 enable	 realisation	 of	 products	 to	 patients.	
Improvements	to	the	manufacturing	process	and	test	methods	should	also	be	an	important	
priorty	 for	 pharmaceutical	 companies.	 As	 new	 knowledge	 is	 discovered	 throughout	 the	
lifecycle	of	a	product,	continuous	 improvements	must	be	made	 in	order	for	a	company	to	
achieve	its	full	potential,	eliminate	any	supply	disruptions,	reduce	patient	risk	and	improve	
compliance.	 Quality	 of	 a	 drug	 product	 and	 its	 process	 effectiveness	 can,	 and	 should	 be	
demonstrated	throughtout	its	entire	lifespan.	Without	implementing	changes	along	the	way	
there	would	be	no	improvements.		




efficacy	of	 the	medicines	 	available	 to	patients.	The	EU	regulatory	authority	 the	European	
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Medicines	Agency	 (EMA)	 	has	pubished	a	questions	and	answers	document	on	 regulatory	
expectations	 for	medicinal	products	 for	human	use	 [1].	The	aim	of	 the	EU	 legislation	 is	 to	
ensure	a	high	level	of	public	health	is	maintained,	while	providing	regulatory	flexibility.	The	
US	 regulatory	 authority	 the	 Food	 and	 Drug	 Administration	 (FDA)	 have	 established	 an	




of	 medicines	 	 to	 clinical	 trials,	 industry	 and	 regulatory	 changes	 have	 been	 focused	 on	
minimising	 risks	 of	 drug	 shortages	 while	 maintaining	 the	 priority	 of	 quality,	 safety,	 and	
efficacy	of	medicines.	
The	 International	 Council	 for	 Harmonisation	 (ICH)	 provide	 quality	 guidelines	 across	 the	
product	 lifecycle	 including:	 Q8(R2)	 Pharmaceutical	 Development	 [3],	 (Q9)	 Quality	 Risk	
Management	 [4],	 (Q10)	 Pharmaceutical	 Quality	 System	 [5]	 and	 (Q11)	 Development	 and	
Manufacture	 of	 Drug	 Substances	 [6]	 which	 document	 opportunities	 for	 science	 and	 risk-
based	 approaches	 for	 assessing	 and	managing	 changes.	 However,	 it	 is	 clear	 from	 recent	
drug	shortages	that	there	are	still	challenges	for	both	industry	and	regulatory	bodies	which	
limit	 in	paticular	any	benefits	 from	 improvements	being	made	 in	 the	commercial	 stage	of	
the	 pharmaceutical	 lifecycle.	 In	 paticular	 the	 process	 for	 post	 approval	 changes	 (PAC)	 for	
innovation	 and	 continuous	 improvement	 has	 been	 identified	 as	 an	 area	 that	 needs	more	
focus[7].		
Building	 on	 the	 ICH	 Q8-Q11	 series	 of	 guidelines,	 ICH	 Q12	 Technical	 and	 Regulatory	
Considerations	 for	 Pharmaceutical	 Product	 Lifecycle	 Management	 [8]	 was	 finalised	 in	
Novmber	 2019.	 This	 guideline	 addresses	 the	 commercial	 (post	 approval)	 phase	 of	 the	
product	lifecycle	and	it	both	complements	and	adds	to	the	flexible	regulatory	approaches	to	
post-approval	Chemistry	Manufacturing	Control	(CMC)	changes	described	in	ICH	Q10	Annex	
1.	 ICH	 Q12	 provides	 a	 framework	 to	 facilitate	 the	 management	 of	 post-approval	 CMC	
changes	 in	 a	 more	 predictable	 and	 efficient	 manner.	 A	 harmonised	 approach	 regarding	
technical	 and	 regulatory	 considerations	 for	 lifecycle	management	 should	benefit	 patients,	
industry,	and	regulatory	authorities	by	promoting	 innovation	and	continual	 improvements	
in	 the	 pharmaceutical	 sector,	 strengthening	 quality	 assurance	 and	 improving	 supply	 of	
medicinal	 products.	 It	 	 also	 demonstrates	 how	 increased	 product	 and	 process	 knowledge	
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guidance	 for	 GMP	 inspectors	when	 seeking	 to	 evaluate	 the	 effectiveness	 of	 a	 company’s	
pharmaceutical	quality	system	(PQS)	in	relation	to	risk-based	change	management.		
This	 was	 followed	 by	 a	 review	 of	 the	 Post	 Approval	 Change	 Literature	 provided	 by	 The	
World	Health	Organisation	(WHO)	[11],	the	US	Food	and	Drug	Administration	(FDA)	[12],	the	
European	 Medicines	 Agency	 (EMA)	 [13]	 and	 the	 Japanese	 Pharmaceutical	 and	 Medical	
Devices	Agency	(PDMA)	[14].		
Finally,	 two	 recent	publications	 in	 relation	 to	post	approval	 change	 in	 the	pharmaceutical	
industry	were	also	reviewed	namely:	 Industry	One-Voice-of	Quality	Concept	Paper:	Solving	
the	 Global	 Continual	 Improvement	 and	 Innovation	 Challenge:	 How	 an	 Effective	
Pharmaceutical	 Quality	 System	 Can	 Transforms	 Post-Approval	 Change	 Management	 [15]	









The	 purpose	 of	 the	 literature	 review	 was	 to	 understand	 how	 post	 approval	 change	 is	
managed	 within	 the	 pharmaceutical	 industry	 and	 what	 guidance	 the	 pharmaceutical	





This	 guideline	 describes	 the	 suggested	 contents	 for	 Section	 3.2.P.2	 (Pharmaceutical	




Authorisation	Holder	 (MAH)	an	opportunity	 to	present	 the	knowledge	gained	through	the	
application	 of	 scientific	 approaches	 and	 quality	 risk	 management	 (ICH	 Q9	 QRM)	 to	 the	
development	of	a	product	and	its	manufacturing	process.	It	is	first	produced	for	the	original	
marketing	 application	 and	 can	 be	 updated	 to	 support	 new	 knowledge	 gained	 over	 the	
lifecycle	 of	 a	 product.	 It	 is	 intended	 to	 provide	 a	 comprehensive	 understanding	 of	 the	
product	 and	 manufacturing	 process	 for	 reviewers	 and	 inspectors.	 The	 guideline	 also	
indicates	areas	where	 the	demonstration	of	greater	understanding	of	pharmaceutical	and	




Authorisation	Holder	 (MAH)	an	opportunity	 to	present	 the	knowledge	gained	through	the	
application	 of	 scientific	 approaches	 and	 quality	 risk	 management	 (ICH	 Q9	 QRM)	 to	 the	
development	of	a	product	and	its	manufacturing	process.	It	is	first	produced	for	the	original	
marketing	 application	 and	 can	 be	 updated	 to	 support	 new	 knowledge	 gained	 over	 the	
lifecycle	 of	 a	 product.	 It	 is	 intended	 to	 provide	 a	 comprehensive	 understanding	 of	 the	
product	 and	 manufacturing	 process	 for	 reviewers	 and	 inspectors.	 The	 guideline	 also	
indicates	areas	where	 the	demonstration	of	greater	understanding	of	pharmaceutical	and	
manufacturing	 sciences	 can	 create	 a	basis	 for	 flexible	 regulatory	 approaches.	 ICH	Q8	also	
4










This	 guideline	 gives	 principles	 and	 examples	 of	 tools	 that	 can	 enable	 effective	 and	









Good	 Manufacturing	 Practice	 (GMP)	 regulations..	 Figure	 1	 shows	 the	 ICH	 Q10	
Pharmacecutical	Quality	System	elements	and	enablers.	Change	management	system	is	one	











which	 subsequently	 strengthens	 the	 confidence	 Regulatory	 Authoritiess	 have	 in	 a	
company’s	ability	to	consistently	produce	high	quality	products.	A	risk-based	assessment	of	




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































HUMAN	 USE	 DURING	 THE	 COVID-19	 PANDEMIC,	 Brussels,	 10	 April	 2020	 (Revision	 3	 –	 1	 July	
2020)	
2.) Emergency	Use	Authorization	of	Medical	Products	and	Related	Authorities,	Guidance	for	Industry	
and	 Other	 Stakeholders,	 U.S.	 Department	 of	 Health	 and	 Human	 Services	 Food	 and	 Drug	
Administration,	January	2017	
3.) ICH,	 “Pharmaceutical	 Development	 Q8	 (R2),”	 ICH	 Harmonised	 Tripartite	 Guideline,	 vol.	 8,	 no.	
August,	pp.	1–28,	2009.	
4.) International	 Conference	 on	 Harmonisation,	 Quality	 Guideline	 Q9:	 Quality	 Risk	 Management.	
Geneva,	2005.	









8.) International	 Conference	 on	 Harmonisation,	 Quality	 Guideline	 Q12:	 Technical	 and	 Regulatory	
Considerations	for	Pharmaceutical	Product	Lifecycle	Management.	Geneva,	2019.	
9.) INTERNATIONAL	 COUNCIL	 FOR	 HARMONISATION	 OF	 TECHNICAL	 REQUIREMENTS	 FOR	
PHARMACEUTICALSFOR	 HUMAN	 USE,	 ICH	 HARMONISED	 GUIDELINE,	 TECHNICAL	 AND	
REGULATORY	CONSIDERATIONS	FOR	PHARMACEUTICAL	PRODUCT	LIFECYCLE	MANAGEMENT,	
Q12	Annexes,	November	2019	
10.) PHARMACEUTICAL	 INSPECTION	 CONVENTION	 PHARMACEUTICAL	 INSPECTION	 CO-
OPERATION	 SCHEME,	 How	 to	 Evaluate	 /	 Demonstrate	 the	 Effectiveness	 of	 a	 Pharmaceutical	
Quality	System	in	relation	to	Risk-based	Change	Management,	November	2019.	
11.) EXPERT	 COMMITTEE	 ON	 BIOLOGICAL	 STANDARDIZATION,	 Geneva,	 17	 to	 20	 October	 2017,	








15.) Industry	 One-Voice-of	 Quality	 Concept	 Paper:	 Solving	 the	 Global	 Continual	 Improvement	 and	
Innovation	 Challenge:	 How	 an	 Effective	 Pharmaceutical	 Quality	 System	 Can	 Transforms	 Post-
Approval	 Change	Management	 Emma	Ramnarine,	 Anders	 Vinther,	 Kimberly	 Bruhin,	 et	 al.	 PDA	
Journal	of	Pharmaceutical	Science	and	Technology	2019	
16.) Industry	One-Voice-of-Quality	(1VQ)	Solutions,	Effective	Management	of	Post-Approval	Changes	
in	 the	 Pharmaceutical	 Quality	 System	 (PQS)	 -	 Through	 Enhanced	 Science	 and	 Risk-Based	
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